Compare Moderna, Inc. (MRNA) vs Rent the Runway Inc (RENT) Price & Performance

Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.

The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.

Rent the Runway (RENT) trades at $3.70, up 1.65% with a bullish technical signal. The company shows improving fundamentals with Q1 2026 revenue growth of 29.2% to $89.9M and narrowing losses. Despite negative equity of -$182.5M, valuation metrics appear attractive with P/E of 0.48 and P/S of 0.2. Recent leadership transition with Teri Bariquit as interim CEO brings fresh perspective to the subscription fashion platform.

The outlook remains cautiously optimistic with analyst consensus leaning buy (42%) though profitability challenges persist. Key opportunities include subscriber growth and margin improvement, while risks involve high debt load and competitive pressure. The stock offers speculative upside if the company can achieve projected 2026 profitability of $30M net income.